Capsida Biotherapeutics

Executive Summary

Capsida Biotherapeutics is a private, pre-clinical gene therapy platform company headquartered in Thousand Oaks, California, founded in 2019. The company is developing a new class of targeted, non-invasive gene therapies aimed at treating debilitating and life-threatening disorders. Leveraging its proprietary capsid engineering platform, Capsida designs adeno-associated virus (AAV) vectors with enhanced tropism for specific tissues, enabling intravenous delivery that crosses biological barriers such as the blood-brain barrier. This approach potentially improves safety and efficacy compared to conventional gene therapies. While the company has not yet disclosed specific pipeline programs publicly, its platform is broadly applicable to central nervous system (CNS), ocular, and other peripheral indications. Capsida operates at the preclinical stage, focusing on advancing lead candidates toward investigational new drug (IND)-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program70% success
• Q2 2026Presentation of Preclinical Data at Major Conference (e.g., ASGCT)80% success
• TBDAnnouncement of Strategic Partnership or Licensing Deal50% success